KDM6A/B expression has been shown to negatively correlate with survival in patients with CRC, supporting the rationale that inhibiting KDM6A/B may be beneficial for patients with CRC (Fig. 4) [33]. The gene discussed is KDM6A; the disease is colorectal carcinoma.